Background: Clinical worsening (CW) is a composite end point commonly used in
pulmonary arterial hypertension (PAH) trials. We aimed to assess the trial-level surrogacy of …

Background Time to clinical worsening has been proposed as a primary end point in clinical
trials of pulmonary arterial hypertension (PAH); however, neither standardized nor validated …

BACKGROUND The prognostic value of improvement endpoints that have been used in
clinical trials of treatments for pulmonary arterial hypertension (PAH) needs to be further …

Background The evolution in pulmonary arterial hypertension (PAH) management has been
summarised in three iterations of the European Society of Cardiology/European Respiratory …

Background Targeting short-term improvements in multicomponent risk scores for mortality
in patients with pulmonary arterial hypertension (PAH) could result in improved long-term …

Background Pulmonary arterial hypertension is a progressive, fatal disease. Published
treatment guidelines recommend treatment escalation on the basis of regular patient …

Background—Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …

In the summer of 2016, delegates from the German Respiratory Society, the German Society
of Cardiology and the German Society of Pediatric Cardiology met in Cologne, Germany, to …

As the field of PAH develops and progresses, time to clinical worsening may be the best way
currently of distinguishing between the increasing number of treatment options available. A …

At the end of 2013 clinicians managing pulmonary arterial hypertension (PAH) patients have
many more treatment options available to them than they did two decades ago. Basic and …